Irritable Bowel Syndrome 
The MD Magazine Irritable Bowel Syndrome condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Sponsored

Investigational Compound Clears Initial Trial to Treat Serious Gut Disorders
HOST-G904 showed positive results for treating severe bowel conditions.
Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.
Alternative therapies such as probiotics and synbiotics may be viable options for patients with irritable bowel disorders, according to findings published in the British Journal of Pharmacology.
Patients experiencing pain from irritable bowel syndrome (IBS) might find relief from an unlikely source.
Arachnophobes suffering from irritable bowel syndrome (IBS) may have to put their fear on hold to welcome pain relief from their gastrointestinal condition.
The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.
The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.
Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.
The Rome Foundation announced the release of updated and revised Rome IV diagnostic criteria for more than 20 different gastrointestinal disorders at DDW 2016.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$